Adjuvant chemotherapy for tumors of one centimeter or less

the law of diminishing returns.

S. E. Soule, Kathy Miller

Research output: Contribution to journalArticle

Abstract

The role of adjuvant chemotherapy in treatment of breast cancers of 1 cm or less is controversial. Careful consideration must be given to the overall risk of recurrence and death and to the absolute benefit of adjuvant chemotherapy, given that risk. Studies in this group of patients indicate that their overall survival rate is 90% to 99%. The absolute benefit of chemotherapy in this setting is most likely 1% or less. Adjuvant chemotherapy has significant toxicities, including cognitive dysfunction, early menopause, leukemia, and even death. Following a realistic and detailed discussion between patient and oncologist, some patients may choose chemotherapy. However, for the majority of patients with breast cancers of 1 cm or less, the minimal benefit of adjuvant chemotherapy does not justify the risk of the treatment.

Original languageEnglish
Pages (from-to)529-535
Number of pages7
JournalCurrent Oncology Reports
Volume3
Issue number6
StatePublished - Nov 2001

Fingerprint

Adjuvant Chemotherapy
Neoplasms
Breast Neoplasms
Drug Therapy
Menopause
Leukemia
Survival Rate
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adjuvant chemotherapy for tumors of one centimeter or less : the law of diminishing returns. / Soule, S. E.; Miller, Kathy.

In: Current Oncology Reports, Vol. 3, No. 6, 11.2001, p. 529-535.

Research output: Contribution to journalArticle

@article{62d832652828469e875646ef5e3e4aeb,
title = "Adjuvant chemotherapy for tumors of one centimeter or less: the law of diminishing returns.",
abstract = "The role of adjuvant chemotherapy in treatment of breast cancers of 1 cm or less is controversial. Careful consideration must be given to the overall risk of recurrence and death and to the absolute benefit of adjuvant chemotherapy, given that risk. Studies in this group of patients indicate that their overall survival rate is 90{\%} to 99{\%}. The absolute benefit of chemotherapy in this setting is most likely 1{\%} or less. Adjuvant chemotherapy has significant toxicities, including cognitive dysfunction, early menopause, leukemia, and even death. Following a realistic and detailed discussion between patient and oncologist, some patients may choose chemotherapy. However, for the majority of patients with breast cancers of 1 cm or less, the minimal benefit of adjuvant chemotherapy does not justify the risk of the treatment.",
author = "Soule, {S. E.} and Kathy Miller",
year = "2001",
month = "11",
language = "English",
volume = "3",
pages = "529--535",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Adjuvant chemotherapy for tumors of one centimeter or less

T2 - the law of diminishing returns.

AU - Soule, S. E.

AU - Miller, Kathy

PY - 2001/11

Y1 - 2001/11

N2 - The role of adjuvant chemotherapy in treatment of breast cancers of 1 cm or less is controversial. Careful consideration must be given to the overall risk of recurrence and death and to the absolute benefit of adjuvant chemotherapy, given that risk. Studies in this group of patients indicate that their overall survival rate is 90% to 99%. The absolute benefit of chemotherapy in this setting is most likely 1% or less. Adjuvant chemotherapy has significant toxicities, including cognitive dysfunction, early menopause, leukemia, and even death. Following a realistic and detailed discussion between patient and oncologist, some patients may choose chemotherapy. However, for the majority of patients with breast cancers of 1 cm or less, the minimal benefit of adjuvant chemotherapy does not justify the risk of the treatment.

AB - The role of adjuvant chemotherapy in treatment of breast cancers of 1 cm or less is controversial. Careful consideration must be given to the overall risk of recurrence and death and to the absolute benefit of adjuvant chemotherapy, given that risk. Studies in this group of patients indicate that their overall survival rate is 90% to 99%. The absolute benefit of chemotherapy in this setting is most likely 1% or less. Adjuvant chemotherapy has significant toxicities, including cognitive dysfunction, early menopause, leukemia, and even death. Following a realistic and detailed discussion between patient and oncologist, some patients may choose chemotherapy. However, for the majority of patients with breast cancers of 1 cm or less, the minimal benefit of adjuvant chemotherapy does not justify the risk of the treatment.

UR - http://www.scopus.com/inward/record.url?scp=0035514399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035514399&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 529

EP - 535

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 6

ER -